Get the Stockscreener App
168.82
1.44%
2.40
After Hours:
168.82
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $168.82, with a volume of 1.42M.
It is up +1.44% in the last 24 hours and up +0.06% over the past month.
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$166.42
Open:
$166.67
24h Volume:
1.42M
Relative Volume:
1.48
Market Cap:
$18.74B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
22.69
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
-1.66%
1M Performance:
+0.06%
6M Performance:
+9.35%
1Y Performance:
+30.45%
1-Day Range:
$165.76
$169.42
1-Week Range:
$163.00
$178.87
52-Week Range:
$125.09
$178.87
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
168.82 | 18.74B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
SBI Securities Co. Ltd. Takes Position in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Blood Cancer Diagnostics Market Analysis Report 2025-2030, with Quest Diagnostics, Illumina, InVivoScribe, Asuragen, Danaher, Sequenta, SkylineDx, Bio-Rad Laboratories, Alercell & Sophia Genetics - Yahoo Finance
Catherine T. Doherty Sells 5,370 Shares of Quest Diagnostics Incorporated (NYSE:DGX) Stock - Defense World
Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock By Investing.com - Investing.com Australia
Mutual of America Capital Management LLC Decreases Stake in Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Quest Diagnostics EVP Catherine Doherty sells $935,078 in stock - Investing.com India
Quest Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Citigroup Downgrades Quest Diagnostics (NYSE:DGX) to Neutral - Defense World
Quest Diagnostics EVP sells $125,865 in stock - Investing.com
Quest Diagnostics EVP sells $125,865 in stock By Investing.com - Investing.com Australia
SVP, Clinical Solutions Kuppusamy Karthik covered exercise/tax liability with 2,871 shares and was granted 4,434 shares, increasing direct ownership by 14% to 13,119 units (SEC Form 4) - Quantisnow
Labcorp Gains Citi Upgrade While Quest Diagnostics Faces Downgrade On Margin Concerns — Retail Sentiment Mixed - MSN
Quest Diagnostics Incorporated : Your health comes first -March 04, 2025 at 10:54 pm EST - Marketscreener.com
The Analyst Verdict: Quest Diagnostics In The Eyes Of 11 Experts - Benzinga
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Citigroup Downgrades Quest Diagnostics to Neutral From Buy, Price Target is $185 -March 04, 2025 at 05:37 am EST - Marketscreener.com
Quest Diagnostics Stock Hits All-Time High at $176.53 By Investing.com - Investing.com Canada
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge? - Nasdaq
Pine Valley Investments Ltd Liability Co Decreases Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
SVB Wealth LLC Acquires Shares of 68,575 Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
National Pension Service Sells 9,262 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Versor Investments LP Has $664,000 Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics EVP Catherine Doherty sells $142,230 in stock By Investing.com - Investing.com Canada
Quest Diagnostics Incorporated (NYSE:DGX) Shares Purchased by Bank of New York Mellon Corp - MarketBeat
Global Retirement Partners LLC Acquires 173 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
Quest Diagnostics (NYSE:DGX) Reaches New 52-Week HighStill a Buy? - MarketBeat
Quest Diagnostics SVP sells $91,138 in stock By Investing.com - Investing.com South Africa
Quest Diagnostics EVP Catherine Doherty sells $142,230 in stock - Investing.com
Quest Diagnostics SVP sells $91,138 in stock - Investing.com India
IFP Advisors Inc Has $2.35 Million Stock Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
QRG Capital Management Inc. Purchases 2,012 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Atria Wealth Solutions Inc. Purchases 425 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - Defense World
SEC Form 144 filed by Quest Diagnostics Incorporated - Quantisnow
Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.80 - Yahoo Finance
New Jersey Court Applies CIPA’s Party Exception to Pixel Wiretap Complaint - Inside Privacy
New York State Common Retirement Fund Sells 6,987 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest to buy Fresenius Medical Care kidney testing assets - MedTech Dive
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? - MSN
Are Wall Street Analysts Bullish on Quest Diagnostics Stock? - MSN
Fresenius Medical Care Divests Laboratory Assets to Quest Diagnostics - TipRanks
FMC AG Divests Select Laboratory Assets To Quest Diagnostics -February 24, 2025 at 08:03 am EST - Marketscreener.com
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics - PR Newswire
Quest Diagnostics to Acquire Select Laboratory Assets of Fresenius Medical Care Unit - Marketscreener.com
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out? - MSN
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus.com
Quest Diagnostics SVP Michael Prevoznik sells $103,277 in stock By Investing.com - Investing.com Australia
Quest Diagnostics SVP Plewman sells $54,307 in stock By Investing.com - Investing.com Australia
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):